PRESTIGE CONSUMER HEALTHCARE INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-05-06.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax · last filed 2022-05-06
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, tax for fiscal 2021 was $543.00K, a 62.63% decline from fiscal 2020.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, tax for fiscal 2020 was $1.45M.
- PRESTIGE CONSUMER HEALTHCARE INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, tax for fiscal 2019 was $0.00.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 12 month |
|---|---|
| 2022-03-31 | $0.00 10-K · filed 2022-05-06 |
| 2021-03-31 | $543.00K 10-K · filed 2022-05-06 |
| 2020-03-31 | $1.45M 10-K · filed 2021-05-07 |
| 2019-03-31 | $0.00 10-K · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |